• Explore /
  • Poster
  • / Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).

Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).

Abstract Poster

Authors

null

James C. Yao

University of Texas M. D. Anderson Cancer Center, Houston, TX

James C. Yao , John D. Hainsworth , Edward M. Wolin , Marianne E. Pavel , Eric Baudin , David Gross , Philippe Ruszniewski , Paola Tomassetti , Ashok Panneerselvam , Stephen Saletan , Judith Klimovsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT00412061

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4014)

DOI

10.1200/jco.2012.30.15_suppl.4014

Abstract #

4014

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: James Yao

First Author: Lowell Anthony

First Author: Edward Wolin

First Author: Jonathan R. Strosberg